Evaluation Sub-Committee - Applications scheduled to be considered

• 1734 - Intravascular lithotripsy for the treatment of moderately or severely calcified peripheral artery disease
• 1760 - DPYD genotyping to predict fluoropyrimidine-induced toxicity
• 1761 - Faecal calprotectin for the monitoring of disease activity in patients with inflammatory bowel disease
• 1766 - Genetic testing to detect AKT-pathway alterations in patients with hormone receptor-positive, HER2-negative advanced breast cancer, to determine eligibility for PBS subsidised capivasertib treatment
• 1775 - Newborn bloodspot screening for mucopolysaccharidosis, Type 1 (MPS I)

Consultation Input:

MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.

It is anticipated that the above-mentioned applications will proceed to MSAC in November 2024. Consultation input must be received by no later than Friday, 11 October 2024 for it to be considered by MSAC. A link to the Consultation Survey is available on the relevant application webpage.

Further information on MSAC’s consultation process is also available on the MSAC website.